Anti-cyclic citrullinated peptide antibodies (ACCP) especially those against cyclic citrullinated peptide-2 (CCP2) have been proven to accurately predict both the onset of RA and the extent of concomitant joint damage [53]. The gene discussed is AGBL2; the disease is rheumatoid arthritis.